We have located links that may give you full text access.
Biochemical Recurrence of Prostate Cancer: Initial Results with [ 18 F]PSMA-1007 PET/CT.
Journal of Nuclear Medicine 2018 April
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68 Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18 F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18 F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18 F-PSMA-1007. Results: 18 F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18 F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax , 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18 F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18 F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app